This systematic review established the biphasic framework for cannabis and anxiety: low doses reduce anxiety via CB1 receptors on excitatory neurons, while high doses increase anxiety by also suppressing inhibitory GABA circuits.
Readers trying to parse whether cannabis causes anxiety, whether anxious people are more likely to use cannabis, or whether both are true for different reasons.
0definitive causal links found between cannabis use and chronic anxiety disorders in this 2009 review
The Backstory
Here's a story cannabis users know but science took decades to explain: the same joint that melts your stress at two puffs can send you into a full-blown panic attack at six. The same person who swears cannabis is their anti-anxiety medication is also the person who once had to call a friend at 2 AM because they were convinced they were dying.
Cannabis doesn't have a single relationship with anxiety. It has two — and they point in opposite directions. José Crippa's 2009 review was the first comprehensive attempt to map this paradox, pulling together decades of fragmented evidence into a single framework that explained why the cannabis-anxiety question has no simple answer.
The Paradox
Crippa and colleagues — working from the University of São Paulo's Ribeirão Preto medical school, the same group behind the landmark CBD anxiety trial — systematically searched Medline, PsycLIT, and EMBASE for every human study connecting cannabis to anxiety. What they found was a portrait of contradiction.
Frequent cannabis users had significantly higher rates of anxiety disorders than non-users. People with anxiety disorders were significantly more likely to use cannabis. Acute cannabis intoxication frequently triggered panic attacks and severe anxiety episodes. Yet many users reported cannabis as their primary tool for managing anxiety. And the evidence that cannabis caused lasting anxiety disorders? Essentially absent.
The data was pointing in every direction at once — because, as subsequent research would reveal, cannabis genuinely does go in every direction at once.
The Biphasic Dose-Response
The most important concept to emerge from this body of research is the biphasic dose-response curve: the observation that cannabinoids produce opposite effects at different doses. This isn't a quirk or an inconsistency. It's the pharmacology.
Biological Mechanism
Why the Same Drug Calms and Terrifies
Low dose THC enters the brain
At low doses (roughly 2.5-5 mg in humans), THC preferentially activates CB1 receptors on glutamatergic (excitatory) nerve terminals in the amygdala and prefrontal cortex.
Glutamate release decreases
CB1 activation on excitatory terminals reduces glutamate output. Less excitatory signaling in the amygdala means less threat processing, less catastrophic thinking, less anxiety.
Net effect: anxiolytic
The brain's alarm system quiets down. The person feels calmer, less worried, more relaxed. This is the cannabis-as-medicine experience.
High dose THC saturates the system
At higher doses (roughly 15 mg+ in low-tolerance users), THC begins activating a different population of CB1 receptors — those on GABAergic (inhibitory) interneurons.
GABA release decreases
Reducing inhibitory GABA output removes the brakes on excitatory circuits. The amygdala, now disinhibited, fires excessively.
Net effect: anxiogenic
The brain's alarm system goes into overdrive. Racing heart, paranoid thoughts, sense of impending doom. This is the cannabis panic attack.
Rey et al. (2012), Neuropsychopharmacology; Crippa et al. (2009)
The critical insight is that these aren't different effects of THC — they're the same effect (CB1 receptor activation) on different cell types. At low doses, CB1 activation preferentially dampens excitatory glutamate signaling, producing calm. At high doses, it also dampens inhibitory GABA signaling, removing the neural brakes and producing panic. The transition from medicine to poison depends on which cell population gets recruited.
The Numbers Behind the Curve
Dose-Response
Cannabis and Anxiety: Where the Curve Flips
Anxiolytic range: ~2.5-7.5 mg THC
Multiple human studies show low-dose THC reduces anxiety, tension, and stress ratings. This is the 'therapeutic window' for anxiety relief.
Neutral zone: ~7.5-12.5 mg
Effects are variable, dependent on individual tolerance, genetics, context, and CBD content. Most people are fine; some start getting anxious.
Anxiogenic range: ~15 mg+
In low-tolerance users, doses above 15 mg consistently increase anxiety, panic symptoms, and paranoia in controlled studies.
Individual variation is enormous
A daily user might comfortably tolerate 50 mg. A naive user might panic at 10 mg. Tolerance, genetics (particularly the FAAH gene), and concurrent CBD content all shift the curve.
CBD modulates the curve
CBD appears to counteract THC-induced anxiety. Products with higher CBD:THC ratios have wider anxiolytic windows. Pure THC products have narrower ones.
Crippa et al. (2009); Childs et al. (2017); Bhattacharyya et al. (2010)
These numbers are approximate because the curve is highly individual. But the general pattern is remarkably consistent across studies: low THC calms, high THC panics, and the threshold between them varies by person. This is why the same strain that helps one person sleep can give another person a panic attack — and why people who once loved cannabis can suddenly find it anxiety-provoking when their tolerance changes.
The Self-Medication Trap
Crippa's review identified a second paradox beyond the dose-response: the self-medication cycle. People with anxiety disorders are more likely to use cannabis — presumably because low-dose cannabis genuinely reduces their anxiety. But cannabis use is also associated with higher rates of anxiety disorders. These observations aren't contradictory; they describe a trap.
Process
The Cannabis-Anxiety Self-Medication Cycle
Anxiety disorder exists
Social anxiety, generalized anxiety, or panic disorder — often undertreated or undiagnosed.
Cannabis provides relief
At low doses, cannabis reduces acute anxiety. The person discovers a tool that works quickly and doesn't require a prescription.
Tolerance develops
Over weeks to months, the anxiolytic dose increases. What once worked at 5 mg now requires 15 mg.
The curve shifts
The higher dose crosses into the anxiogenic range. Cannabis that once calmed now sometimes panics.
Withdrawal anxiety compounds
Between sessions, cannabis withdrawal produces rebound anxiety — often worse than baseline. The person uses more cannabis to treat it.
The disorder persists, untreated
Cannabis manages acute symptoms but doesn't address the underlying condition. Professional treatment is delayed because cannabis 'works' — until it doesn't.
Study methodology
This cycle is not universal. Many people use cannabis for anxiety successfully for years without escalation. But the review documented that among people who do develop problems, this pattern appeared repeatedly. The cannabis-anxiety relationship isn't "cannabis causes anxiety" or "cannabis treats anxiety" — it's both, in different people, at different doses, at different points in their use trajectory.
What Crippa Couldn't Resolve
The review was honest about what the evidence base couldn't answer in 2009:
Supporting arguments
- First comprehensive mapping of the cannabis-anxiety paradox across multiple research traditions
- Identified the biphasic dose-response as the unifying framework — low dose anxiolytic, high dose anxiogenic
- Distinguished acute intoxication effects (panic attacks) from chronic outcomes (anxiety disorders)
- Documented both self-medication and co-occurrence patterns without forcing a single causal narrative
- Highlighted CBD as a potential moderating variable before the CBD market existed
Limitations and counterarguments
- Could not establish whether cannabis use causes lasting anxiety disorders — correlation only
- Most included studies were observational or cross-sectional, vulnerable to confounding
- Pre-legalization era: THC potency, CBD content, and product types not well characterized
- No pooled effect size or formal meta-analysis — qualitative synthesis only
- The biphasic framework, while conceptually powerful, lacked precise human dose thresholds
- Did not distinguish between different cannabis products, routes, or cannabinoid profiles
Crippa et al. (2009)
The fundamental limitation was temporal. In 2009, the high-potency THC concentrates, CBD-dominant products, and diverse edible formulations that now dominate legal markets didn't exist. The "cannabis" in most studies was whatever uncharacterized product participants reported using. Whether the biphasic framework holds precisely across different cannabinoid ratios, delivery methods, and potencies is a question that 2009 couldn't answer and 2026 is still working on.
Why This Framework Still Matters
Fifteen years later, the biphasic dose-response remains the single most useful concept for understanding cannabis and anxiety. It explains:
- Why the same person can have opposite experiences with the same strain
- Why microdosing works for anxiety when higher doses don't
- Why CBD-dominant products are more reliably anxiolytic than THC-dominant ones
- Why the clinical advice "start low, go slow" is pharmacology, not just caution
- Why edibles are particularly prone to causing panic attacks — the delayed onset leads to re-dosing before the first dose takes effect, pushing people past their threshold
If there is a single piece of knowledge that would prevent the most cannabis-related harm, it might be this: the dose that relaxes you is close to the dose that terrifies you, and the boundary is invisible until you cross it.
Key Takeaways
Cannabis and anxiety: a critical review of the evidence
Crippa JAS, Zuardi AW, Martín-Santos R, Bhattacharyya S, Atakan Z, McGuire P, Fusar-Poli P (2009) · Human Psychopharmacology: Clinical and Experimental
Why does cannabis sometimes help my anxiety and sometimes make it worse?
Because of the biphasic dose-response. At low doses, THC reduces anxiety by dampening excitatory brain circuits. At higher doses, it also suppresses inhibitory circuits, removing the brain's brakes and producing panic. Your threshold between these effects depends on your tolerance, genetics, the product's CBD content, your emotional state, and the environment. The same dose in different circumstances can produce opposite effects.
Is cannabis good or bad for anxiety?
Both, depending on dose, product, person, and pattern of use. Low-dose cannabis with balanced CBD:THC ratios appears to be anxiolytic for many people. High-dose, high-THC products without CBD are more likely to provoke anxiety. Chronic heavy use can worsen anxiety through tolerance and withdrawal effects. The question isn't whether cannabis affects anxiety — it's how, at what dose, in whom, and over what timeframe.
Should I use cannabis to treat my anxiety disorder?
This review found that cannabis can provide acute relief but doesn't treat underlying anxiety disorders. For many people, the self-medication pattern leads to tolerance, dose escalation, and eventually worse anxiety. If you have a diagnosed anxiety disorder, evidence-based treatments (CBT, SSRIs) have stronger long-term outcome data. If you choose to use cannabis for anxiety, keep doses very low, prefer CBD-dominant products, and don't use it as a substitute for professional treatment.
Does CBD have the same biphasic effect as THC?
No. CBD does not appear to produce the same dose-dependent flip from anxiolytic to anxiogenic. Across dose ranges tested in human studies, CBD has been consistently calming or neutral — though very high doses may be less effective than moderate doses (an inverted U pattern, not a biphasic flip). This is one reason CBD-dominant products are generally recommended over THC-dominant ones for anxiety.
What the researchers found
Acute anxiety reactions and panic attacks were commonly reported during cannabis intoxication. Across observational studies, two patterns showed up repeatedly: frequent cannabis users had higher rates of anxiety disorders, and people with anxiety disorders reported higher rates of cannabis use. The review could not show that cannabis use leads to persistent anxiety disorders. Explanations ranged from neurobiology to environment and social context, including self-medication, shared vulnerability, and confounding by stress and other substance use. The bottom line in 2009 was correlation in both directions without a clear causal pathway.
Why it matters
Anxiety is one of the most commonly cited reasons people discuss cannabis, and also one of the most frequently reported adverse reactions during intoxication. This review mapped what was known in 2009, separating acute panic-like reactions from questions about longer-term anxiety disorders, and highlighted how easily co-occurrence can be misread as causation.
The numbers in context
- Databases searched: 3 (Medline, PsycLIT, EMBASE)
- Publication year: 2009, before today’s higher-potency products and concentrates were widespread
- Causality: 0 studies in the review established a definitive causal link to chronic anxiety disorders
- Pattern observed: elevated anxiety rates among frequent users, and elevated cannabis use among people with anxiety disorders, reported across multiple observational samples
How the study worked
A systematic search of Medline, PsycLIT, and EMBASE gathered human studies on cannabis and anxiety. Designs were mostly observational or cross-sectional, with some experimental work focused on acute effects. The review synthesized patterns qualitatively. It did not report a pooled effect size, did not specify the number of included studies, and did not establish temporal ordering between cannabis exposure and the onset of anxiety disorders.
Who was studied
Country not specified.
What this study cannot tell us
The review period predates widespread legal markets and high-potency concentrates. Most included studies were observational or cross-sectional, which cannot establish temporal order or causality and are vulnerable to confounding. Specific product types, THC-to-CBD ratios, dose, frequency, and timing of last use were rarely characterized. Anxiety was measured with varying tools, and acute intoxication effects were sometimes conflated with chronic disorders. Publication bias and unmeasured comorbidities, including alcohol and tobacco, were likely.
How to read the evidence
Rated moderate: a systematic review across three databases, but the evidence base was largely observational, heterogeneous, and lacked pooled estimates or strong longitudinal data.
When this study was published
Published in 2009. Preceded today’s legal markets, higher-potency products, and routine reporting of THC-to-CBD ratios, which limits direct applicability to current use patterns.
The bigger picture
The anxiety–cannabis relationship is often presented as simple. It is not. Acute anxiety during intoxication can be real, yet that does not automatically translate into a lasting anxiety disorder. Observational links in both directions are consistent with several scenarios: people with anxiety using cannabis to cope, shared risk factors driving both, or subgroups responding differently depending on dose, potency, age of first use, and context. This review set a baseline for those debates in the pre-legalization era when products, potencies, and measurement standards differed from today.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Does frequent cannabis use predict future anxiety disorders after adjusting for baseline anxiety, trauma, and other substance use?
- Do THC potency, CBD content, and route of administration track with different anxiety outcomes?
- Are adolescents and young adults more susceptible than older adults to anxiety-related outcomes linked to cannabis use?
- How much of the observed association reflects withdrawal or rebound anxiety rather than intoxication effects?
- Do genetic or sex differences modify anxiety responses to cannabis?
Common questions
Did the review show that cannabis causes anxiety disorders?
What about panic attacks after using cannabis?
Were potency or CBD content considered?
Could people with anxiety be using cannabis to cope?
Read the original research
Cannabis and anxiety: a critical review of the evidence
Human Psychopharmacology: Clinical and Experimental, 24(7), 515-523
Human Psychopharmacology: Clinical and Experimental is a peer-reviewed journal focusing on the effects of drugs on human behavior and mental processes.
Citation
Crippa, Jose Alexandre S.; Zuardi, Antonio Waldo; Martin-Santos, Rocio; Bhattacharyya, Sagnik; Atakan, Zerrin; McGuire, Philip; Fusar-Poli, Paolo. (2009). Cannabis and anxiety: a critical review of the evidence. Human Psychopharmacology: Clinical and Experimental, 24(7), 515-523.
Explore the wider topic
- Weed Withdrawal Anxiety in Public: When Leaving the House Feels Impossible
- The DARE Response to Anxiety for Cannabis Withdrawal
- The Cannabis Withdrawal Anxiety Toolkit: Quick Techniques That Work
- Why Anxiety Gets Worse Before It Gets Better After Quitting Weed
- Breathing Exercises for Weed Withdrawal Anxiety
- Cannabis-Induced Anxiety: When Weed Stops Being Fun
- Does Weed Help or Hurt Anxiety? What Research Actually Shows
- Grounding Techniques for Cannabis Withdrawal: A Practical Toolkit
- Quitting Weed with Health Anxiety: Why Every Symptom Feels Like a Crisis
- How to Manage Anxiety Without Weed: 15 Evidence-Based Alternatives
- Quitting Weed with Anxiety Disorder: A Careful Approach
- Quitting Weed When You're on Anxiety Medication: What to Know
- Self-Medicating Anxiety with Weed: Why It Works Until It Doesn't
- Do I Need Therapy to Quit Weed? When Professional Help Makes Sense
- Weed and Anxiety: The Paradox That Traps People
- The Biphasic Effect: Low-Dose Calms, High-Dose Panics
- Weed and Generalized Anxiety Disorder (GAD): Why It Backfires
- Weed and Panic Attacks: The Connection Nobody Talks About
- Weed and Paranoia: When Cannabis Turns Your Mind Against You
- Weed and Social Anxiety: Why It Feels Like the Only Thing That Helps
- Why Weed Stopped Working for Your Anxiety
- Weed Withdrawal Anxiety: Understanding the Panic and How to Cope
- Weed Withdrawal Panic Attacks at Night: Why They Happen and How to Get Through Them
- Going Back to Work During Weed Withdrawal: Managing Anxiety and Staying Functional
- Withdrawal Anxiety vs Pre-Existing Anxiety: How to Tell the Difference
- Why Does Weed Make You Paranoid? The Amygdala Connection
- Why Does Weed Make Me Anxious Now When It Didn't Before
- THC and Benzodiazepines: The Dangerous Overlap Nobody Discusses
- Cannabis and Socializing: Why Some People Only Use Around Others